Pulse Biosciences Announces Redemption of 200% Warrants: Key Details for Investors
Summary of the Event
On June 10, 2026, Pulse Biosciences, Inc. (Nasdaq: PLSE) announced that it will deliver an irrevocable notice of redemption for all remaining outstanding common stock warrants (the “200% Warrants”) issued in connection with its July 3, 2024, rights offering. This action follows the satisfaction of the redemption condition, which required the Company’s volume weighted average price (VWAP) to exceed \$22.00 per share for twenty consecutive trading days at least three months after the warrants’ issuance date. Pulse Biosciences confirmed that this requirement was met, with the average VWAP being \$25.17 during the qualifying period.
Key Points for Investors
- Redemption Details: Holders of the 200% Warrants may exercise their warrants at an exercise price of \$11.00 per share until 5:00 p.m. Eastern Time on July 13, 2026. Any 200% Warrants that remain unexercised by that deadline will be redeemed by Pulse Biosciences for just \$0.01 per warrant share.
- Redemption Triggered by Share Price: The Company’s VWAP exceeded 200% of the warrant exercise price (\$22.00) for twenty consecutive trading days, triggering the right to redeem the 200% Warrants.
- Previous Warrant Redemptions: The Company had previously redeemed the first tranche of “150% Warrants” in February 2025. None of these are currently outstanding.
- Proceeds to Date: Pulse Biosciences received gross proceeds of \$60 million from the initial Rights Offering (July 2024). It has also received \$63.7 million in gross proceeds from the redemption of the 150% and 200% Warrants to date. If all remaining 200% Warrants are exercised before the redemption date, the Company will receive an additional \$2.1 million.
- Instructions for Warrant Holders: If you hold 200% Warrants, you must act before July 13, 2026, to exercise them and receive common stock at a significant discount to recent market prices. After the deadline, each unexercised warrant will be redeemed for only \$0.01 per share.
- Impact on Capital Structure: The exercise of all outstanding 200% Warrants has the potential to increase the Company’s cash reserves and common shares outstanding, which may impact share value and dilution.
Why Is This Important for Shareholders?
This is a price-sensitive development. The redemption of the 200% Warrants may influence Pulse Biosciences’ share price in several ways:
- Potential Dilution: If all outstanding warrants are exercised, the Company will issue additional shares, which may dilute existing shareholders but also adds cash to the Company’s balance sheet.
- Cash Inflow: The exercise of warrants at \$11.00 per share (when the market price is over \$22.00) provides the Company with immediate capital, strengthening its financial position.
- Redemption Deadline: Shareholders who hold the 200% Warrants need to decide whether to exercise their warrants or accept a nominal redemption price of \$0.01 per share after July 13, 2026.
Next Steps and Actions for Investors
- Warrant holders should review their positions and consider exercising warrants before the July 13, 2026, deadline to capitalize on the favorable exercise price.
- Investors should monitor further announcements from Pulse Biosciences, including updates on the total number of warrants exercised and the Company’s use of proceeds.
- The official notice of redemption will be available on the Company’s investor relations website.
- Questions regarding redemption and exercise can be directed to Broadridge Corporate Issuer Solutions, LLC at 888-789-8409 or [email protected].
About Pulse Biosciences
Pulse Biosciences is a medical technology company leveraging its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for non-thermal tissue ablation. The Company is pursuing development of its nPulse technology for the treatment of atrial fibrillation and other markets where it may have a significant impact on healthcare.
Contact Information
- Company Contact: Jon Skinner, CFO ([email protected])
- Investor Relations: Gilmartin Group, Philip Trip Taylor ([email protected], 415.937.5406)
Disclaimer: This article contains forward-looking statements based on current expectations and projections, which may differ from actual results due to risks and uncertainties. No representation or recommendation is made to any investor regarding the exercise of warrants or investment decisions. Investors should conduct their own due diligence and consult with their financial advisors. This article is not an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction where such would be unlawful.
